We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Metabolon Announces Quantose IR Test Launched in Mexico
Product News

Metabolon Announces Quantose IR Test Launched in Mexico

Metabolon Announces Quantose IR Test Launched in Mexico
Product News

Metabolon Announces Quantose IR Test Launched in Mexico


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Metabolon Announces Quantose IR Test Launched in Mexico"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Metabolon has announced that its Quantose IR™ prediabetes test is now available to physicians in Mexico through PATIA Biopharma, its commercial partner there.

In addition, PATIA and its affiliates will be using Quantose IR in two large-scale studies to test up to three million adults and teenagers in Mexico who are overweight or obese and/or have a family history of diabetes.

It is estimated that one out of every five adults in Mexico has prediabetes, a condition that often progresses to type 2 diabetes if left untreated. Early detection is crucial, because prediabetes can be reversed with lifestyle changes and treatment.

With Quantose IR, PATIA has a new tool to aid doctors and patients in making informed and timely decisions that could potentially delay or prevent the onset of type 2 diabetes, a serious public health issue affecting more than 10 percent of the adult population in Mexico.

In fact, an average of eight people die in that country every hour from complications related to the disease, according to the IDF Diabetes Atlas.

Quantose IR is a convenient, cost-effective test that requires only a single fasting blood sample. The test measures the blood concentration levels of specific metabolites, making it possible to detect insulin resistance, an early indication of prediabetes.

In February 2014, Metabolon and PATIA have announced a strategic alliance agreement naming PATIA the exclusive commercial partner for Quantose IR in Mexico. All testing will be performed at the Clínica Ruiz laboratories, which are certified by the American National Accreditation Board (ANAB).

“We’re proud that Quantose IR is now commercially available in Mexico through a dynamic collaboration with PATIA Biopharma,” stated John Ryals, Ph.D., President and CEO at Metabolon. “Treatment of type 2 diabetes is an enormous and rising cost worldwide, and awareness of prediabetes is the first step to avoiding progression. There is no cure for type 2 diabetes, so prevention offers tremendous potential to begin reversing the course of this growing epidemic.”

Advertisement